3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
US11066396B2 · kind B2 · utility
0Cited by
18References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 19, 2017 |
| Grant date | Jul 20, 2021 |
| Priority date | — |
| Expiry date | Jun 19, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F7/0807
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.